Gary Hobbs and his wife, Lori, have built BWI LLC into a fast-growing developer of affordable housing with 48 employees and more than $10 million in annual revenue.
Eli Lilly and Co. got good news and bad news about its top-selling drug, the lung cancer therapy Alimta. According to Bloomberg News, a British court upheld a patent protecting a vitamin regimen administered with the drug and said that patent would be infringed by a generic competitor. Lilly's patent protecting Alimta's chemical makeup expires […]
Eli Lilly and Co. is preparing to release data on its experimental Alzheimer’s disease treatment, solanezumab, after years of sometimes positive but often discouraging research.
Indiana’s latest pitch to lure business received national attention and stirred up some controversy. Yet that is exactly what a full-page ad in The Wall Street Journal is meant to do. So, mission accomplished.
London Mayor Boris Johnson is proposing a $16 billion fund to encourage growth of emerging health-care companies in the United Kingdom in an effort to catch up to biotechnology clusters in the United States.
Eli Lilly and Co. received some European legal backing for its top product, the lung cancer treatment Alimta, on Thursday when a British court upheld a patent protecting a vitamin regimen administered with the drug.
Eli Lilly and Co. has been ordered to face claims it misled consumers about “brain zaps” and other withdrawal side effects tied to its antidepressant Cymbalta in the first cases slated to be heard by juries.
In a new scoring system for oncology drugs, a leading group of U.S. cancer doctors awarded a zero for overall benefit to a regimen featuring Alimta, Eli Lilly and Co.’s top-selling product.
Eli Lilly and Co.’s shares have risen more than 5 percent this month—and more than 20 percent so far this year—as its pipeline has delivered a string of positive results. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs. And next month, Lilly will release more data […]
After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
Noblesville-based Diamond Charts LLC has become a huge hit among college baseball teams big and small since two Rose-Hulman Institute of Technology alumni launched it in early 2013 with $200 and what seemed like a crazy idea.
Anthem Blue Cross and Blue Shield has added St. Vincent Health to the “narrow network” of health care providers it uses for Obamacare plans. St. Vincent’s 22 hospitals and nearly 900 physicians on June 1 joined the network Anthem uses for individual health plans it sells on the online exchange created by the Affordable Care […]
Axovant Sciences Ltd., a company without a finished product or a dime of sales, has an almost $3 billion valuation after its public-market debut. The IPO shows the staggering potential for any company that can develop a successful Alzheimer’s treatment.
Indianapolis-based Eli Lilly and Co. plans to introduce its version of Sanofi’s Lantus insulin for diabetes in Europe in the third quarter, said Enrique Conterno, the president of Lilly Diabetes.
An experimental pill to treat low sexual desire in women moved closer to becoming the first such drug to be sold in the U.S. after regulatory advisers backed its approval.
Assets in 2014 rose from $7.7 billion to $10.1 billion, a 31-percent surge. The value of the endowment now has nearly doubled since closing 2010 at $5.3 billion.
